Renaissance Technologies LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX)

Renaissance Technologies LLC grew its stake in Immunic, Inc. (NASDAQ:IMUX) by 45.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 566,623 shares of the company’s stock after acquiring an additional 177,542 shares during the quarter. Renaissance Technologies LLC owned about 0.63% of Immunic worth $567,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Invesco Ltd. acquired a new stake in shares of Immunic during the 4th quarter worth about $37,000. Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter valued at approximately $50,000. HB Wealth Management LLC acquired a new stake in Immunic during the fourth quarter worth approximately $81,000. Jane Street Group LLC grew its stake in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the period. Finally, State Street Corp raised its holdings in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IMUX. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research report on Wednesday. B. Riley restated a “buy” rating and issued a $6.00 price target on shares of Immunic in a report on Wednesday, April 16th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. William Blair assumed coverage on shares of Immunic in a report on Tuesday, March 25th. They issued an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Thursday. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Immunic presently has an average rating of “Buy” and a consensus price target of $13.20.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.15 on Friday. Immunic, Inc. has a 1 year low of $0.83 and a 1 year high of $2.11. The stock has a 50-day simple moving average of $1.08 and a 200-day simple moving average of $1.11. The stock has a market capitalization of $110.19 million, a P/E ratio of -0.93 and a beta of 1.91.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.